AR046410A1 - Composiciones farmaceuticas para la liberacion modificada de modafinilo - Google Patents
Composiciones farmaceuticas para la liberacion modificada de modafiniloInfo
- Publication number
- AR046410A1 AR046410A1 ARP040103336A ARP040103336A AR046410A1 AR 046410 A1 AR046410 A1 AR 046410A1 AR P040103336 A ARP040103336 A AR P040103336A AR P040103336 A ARP040103336 A AR P040103336A AR 046410 A1 AR046410 A1 AR 046410A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- patient
- modafinilo
- dosage form
- modafinil
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001165 modafinil Drugs 0.000 abstract 5
- -1 modafinil compound Chemical class 0.000 abstract 4
- 239000002552 dosage form Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50402803P | 2003-09-18 | 2003-09-18 | |
| US10/944,528 US8153159B2 (en) | 2003-09-18 | 2004-09-17 | Modafinil modified release pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046410A1 true AR046410A1 (es) | 2005-12-07 |
Family
ID=34381093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103336A AR046410A1 (es) | 2003-09-18 | 2004-09-17 | Composiciones farmaceuticas para la liberacion modificada de modafinilo |
Country Status (20)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
| ATE483455T1 (de) | 2004-05-28 | 2010-10-15 | Transform Pharmaceuticals Inc | Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen |
| US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
| US20100136106A1 (en) * | 2005-06-08 | 2010-06-03 | Gary Liversidge | Modified Release Famciclovir Compositions |
| BRPI0707736A2 (pt) | 2006-02-13 | 2011-05-10 | Vanda Pharmaceuticals Inc | formulaÇÕes de imidazolilalquil-piridinas de dosagem estÁvel |
| JP2009543803A (ja) * | 2006-07-12 | 2009-12-10 | エラン・ファルマ・インターナショナル・リミテッド | モダフィニルのナノ粒子製剤 |
| DE102006035549A1 (de) | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
| US20090082461A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched modafinil |
| JP5250285B2 (ja) * | 2008-03-26 | 2013-07-31 | 富士フイルム株式会社 | 経口物用被覆材、可食性容器およびそれらを用いた経口物 |
| WO2010012407A1 (en) * | 2008-07-29 | 2010-02-04 | Ashland Licensing And Intellectual Property Llc. | Modified additives for suppressing dust formation |
| JP2013530220A (ja) * | 2010-07-06 | 2013-07-25 | ナビファーム.カンパニー リミテッド | ダポキセチンを含む時間差徐放性経口投与型の薬学的組成物 |
| US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
| CA2947528C (en) | 2014-05-01 | 2023-09-05 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
| WO2017058869A1 (en) | 2015-09-29 | 2017-04-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
| MY200542A (en) * | 2017-07-10 | 2024-01-02 | Takeda Pharmaceuticals Co | Preparation comprising vonoprazan |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534263A (en) * | 1995-02-24 | 1996-07-09 | Alza Corporation | Active agent dosage form comprising a matrix and at least two insoluble bands |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6458384B2 (en) | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| US6344215B1 (en) | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
| US7141555B2 (en) | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US7297346B2 (en) | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
| GB0117618D0 (en) | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
-
2004
- 2004-09-17 AR ARP040103336A patent/AR046410A1/es unknown
- 2004-09-17 US US10/944,528 patent/US8153159B2/en not_active Expired - Fee Related
- 2004-09-20 AU AU2004274017A patent/AU2004274017B2/en not_active Ceased
- 2004-09-20 WO PCT/US2004/030815 patent/WO2005027890A1/en not_active Ceased
- 2004-09-20 MY MYPI20043844A patent/MY144755A/en unknown
- 2004-09-20 KR KR1020067005361A patent/KR20060117910A/ko not_active Ceased
- 2004-09-20 ES ES04788862T patent/ES2336215T3/es not_active Expired - Lifetime
- 2004-09-20 EA EA200600590A patent/EA011400B1/ru not_active IP Right Cessation
- 2004-09-20 DE DE602004024220T patent/DE602004024220D1/de not_active Expired - Lifetime
- 2004-09-20 TW TW093128394A patent/TWI344840B/zh not_active IP Right Cessation
- 2004-09-20 BR BRPI0414299-3A patent/BRPI0414299A/pt not_active IP Right Cessation
- 2004-09-20 MX MXPA06003125A patent/MXPA06003125A/es active IP Right Grant
- 2004-09-20 EP EP04788862A patent/EP1670447B1/en not_active Expired - Lifetime
- 2004-09-20 NZ NZ545573A patent/NZ545573A/en not_active IP Right Cessation
- 2004-09-20 CA CA2536666A patent/CA2536666C/en not_active Expired - Fee Related
- 2004-09-20 JP JP2006527123A patent/JP5138932B2/ja not_active Expired - Fee Related
- 2004-09-20 AT AT04788862T patent/ATE448780T1/de not_active IP Right Cessation
-
2006
- 2006-02-14 IL IL173738A patent/IL173738A/en not_active IP Right Cessation
- 2006-02-23 IS IS8327A patent/IS2787B/is unknown
- 2006-02-28 NO NO20060964A patent/NO20060964L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MY144755A (en) | 2011-10-31 |
| EA200600590A1 (ru) | 2006-08-25 |
| TWI344840B (en) | 2011-07-11 |
| NO20060964L (no) | 2006-04-18 |
| US8153159B2 (en) | 2012-04-10 |
| IS8327A (is) | 2006-02-23 |
| ES2336215T3 (es) | 2010-04-09 |
| CA2536666A1 (en) | 2005-03-31 |
| KR20060117910A (ko) | 2006-11-17 |
| EP1670447B1 (en) | 2009-11-18 |
| EA011400B1 (ru) | 2009-02-27 |
| AU2004274017A1 (en) | 2005-03-31 |
| ATE448780T1 (de) | 2009-12-15 |
| NZ545573A (en) | 2010-02-26 |
| US20050095294A1 (en) | 2005-05-05 |
| WO2005027890A1 (en) | 2005-03-31 |
| JP5138932B2 (ja) | 2013-02-06 |
| DE602004024220D1 (de) | 2009-12-31 |
| IL173738A0 (en) | 2006-07-05 |
| HK1089697A1 (en) | 2006-12-08 |
| BRPI0414299A (pt) | 2006-11-14 |
| EP1670447A1 (en) | 2006-06-21 |
| IS2787B (is) | 2012-06-15 |
| AU2004274017B2 (en) | 2010-07-08 |
| IL173738A (en) | 2012-07-31 |
| TW200520748A (en) | 2005-07-01 |
| CA2536666C (en) | 2012-06-19 |
| JP2007518696A (ja) | 2007-07-12 |
| MXPA06003125A (es) | 2006-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
| UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
| AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
| CO6241170A2 (es) | Administracion de oligonucleotidos antisentido complementarios a la apolipoproteina b humana | |
| CR8352A (es) | Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
| AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| AR033688A1 (es) | Composicion parenteral reconstituible | |
| BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| JP2009542623A5 (cg-RX-API-DMAC10.html) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| JPH10505087A (ja) | 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物 | |
| PE20030830A1 (es) | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea | |
| UY28457A1 (es) | Nueva composición | |
| WO2014176417A1 (en) | Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |